Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Masimo (NASDAQ:MASI), a developer of noninvasive patient monitoring products, rose as much as 11% after the company reported its first-quarter earnings results last night.
So what: For the quarter, Masimo saw total revenue rise 14% to $135.9 million, driven by a 14% increase in SET pulse oximetry sales and a 24% jump in Rainbow SET unit sales. Profits rose modestly to $0.28 per share from $0.27 in the previous year and were reduced by $0.03 due to unfavorable currency translation. Wall Street had been expecting Masimo to report a profit of $0.28 per share (in-line with estimates), but only $134.5 million in revenue.
Now what: This was a good report, but perhaps not worthy of a double-digit move higher. Masimo has now met expectations in four of the past five quarters and is going to rely on its newer Rainbow SET to drive bottom-line growth. However, at 17 times forward earnings and with decelerating sales growth, I'm not sold that it's a fantastic value. I believe the best approach here might be to wait and see if it can keep up its double-digit growth for a few more quarters.
Craving more input? Start by adding Masimo to your free and personalized Watchlist so you can keep up on the latest news with the company.
Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.